Conferences IAS 2017
Other Infections
IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- Details
- Category: Search for a Cure
- Published on Thursday, 12 October 2017 00:00
- Written by Gus Cairns
For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).
IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- Details
- Category: Search for a Cure
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
There is a growing overlap between the fields of cancer and HIV cure research, and approaches that help fight one disease may offer clues about the other. This convergence was the theme of the HIV Cure and Cancer Forum preceding the International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris -- the first time cancer has joined the HIV cure agenda.
IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 21 September 2017 00:00
- Written by Keith Alcorn
Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Gus Cairns
Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results from the ANDES study, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
More Articles...
- IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis
- IAS 2017: Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
- IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression
- IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year
- IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
- IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection
- Coverage of the 2017 IAS Conference on HIV Science
- Coverage of the 2017 IAS Conference on HIV Science
- IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners
- IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment
- IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
- IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention
- IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland
- IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study
- IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years
- IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa
- IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report
- IAS 2017: IAS Conference on HIV Science Starts Sunday in Paris
Web Design and Development by